Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a ...

Novel Biologics Demonstrate Targeting of Complement System to Treat Genetic Disease, Ocular Disease and Organ Transplant CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taligen Therapeutics, a biotechnology ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Image of blood cells. KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system. The Food and Drug ...

RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the ...

Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity. C3G ...